NASDAQ$PGNY
Progyny Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Progyny Inc reported Q2 2025 results with revenue growth and continued profitability.
Progyny achieved revenue of $332.9 million in Q2 2025, up 9% year-over-year, driven by increases in both fertility and pharmacy benefits solutions. Net income rose to $17.1 million with operating income of $24.4 million. The company maintained strong utilization metrics and expanded its client base.
- Revenue reached $332.9 million, reflecting 9% growth from Q2 2024.
- Fertility benefits services contributed $213.9 million and pharmacy benefits $118.9 million.
- Net income was $17.1 million with diluted EPS of $0.19.
- ART cycles performed totaled 16,938 with member utilization at 0.55%.
Headline financials
Revenue & EPS history
Progyny · Revenue · Quarterly
$333M
Revenue by segment
Progyny · $333M total across 2 segments · Q2 2025
- Fertility benefits services$214M—64.3%
- Pharmacy benefits services$119M—35.7%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
-1.1%
Avg return
Earnings day
-0.3%
Avg return
5 days after
-0.2%
Avg return
30 days after
38%
11 / 29 earnings
Positive
+26.4%
Q2 2022
Best reaction
-20.5%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +2.5% | +25.4% | +38.2% | |
| Q4 2025 | -20.5% | -20.0% | -22.4% | |
| Q3 2025 | +24.3% | +33.6% | +33.4% | |
| Q1 2025 | -9.7% | -6.5% | -7.2% | |
| Q4 2024 | -1.5% | -5.2% | -4.3% | |
| Q3 2024 | -18.5% | -19.3% | -12.9% | |
| Q2 2024 | -17.7% | -14.7% | -6.4% | |
| Q1 2024 | -14.4% | -14.6% | -14.2% | |
| Q4 2023 | -13.1% | -9.7% | -4.3% | |
| Q3 2023 | -4.3% | -2.1% | +17.8% | |
| Q2 2023 | +4.9% | -2.8% | -8.6% | |
| Q1 2023 | +9.3% | +5.9% | +16.8% | |
| Q4 2022 | +22.9% | +18.4% | +7.7% | |
| Q3 2022 | -2.6% | +2.0% | -13.8% | |
| Q2 2022 | +26.4% | +25.5% | +15.4% | |
| Q1 2022 | -7.1% | -15.6% | -23.1% | |
| Q4 2021 | +11.5% | +13.0% | +31.6% | |
| Q3 2021 | +2.5% | +5.8% | -22.2% | |
| Q2 2021 | -12.8% | -17.1% | +4.3% | |
| Q1 2021 | -3.2% | -8.7% | +18.4% | |
| Q4 2020 | -15.5% | -14.9% | -14.4% | |
| Q3 2020 | -0.3% | +7.0% | +38.7% | |
| Q2 2020 | +0.4% | +8.4% | -0.9% | |
| Q1 2019 | -2.4% | +4.8% | -13.7% | |
| Q1 2020 | +21.8% | +18.8% | +2.1% | |
| Q4 2017 | -3.7% | -6.3% | -8.3% | |
| Q4 2019 | -12.2% | -15.5% | -39.0% | |
| Q4 2018 | -0.2% | -5.0% | -7.0% | |
| Q3 2019 | +0.5% | +0.3% | -6.5% | |
| Q2 2019 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro